-
Something wrong with this record ?
Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists
P. Baji, L. Gulácsi, BD. Lovász, PA. Golovics, V. Brodszky, M. Péntek, F. Rencz, PL. Lakatos,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Biosimilar Pharmaceuticals economics therapeutic use MeSH
- Crohn Disease drug therapy economics MeSH
- Adult MeSH
- Infliximab economics therapeutic use MeSH
- Physicians MeSH
- Practice Patterns, Physicians' statistics & numerical data MeSH
- Middle Aged MeSH
- Humans MeSH
- Antibodies, Monoclonal economics therapeutic use MeSH
- Surveys and Questionnaires MeSH
- Aged MeSH
- Choice Behavior * MeSH
- Health Knowledge, Attitudes, Practice * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Geographicals
- Hungary MeSH
OBJECTIVE: To explore preferences of gastroenterologists for biosimilar drugs in Crohn's disease. MATERIAL AND METHODS: Discrete choice experiment was carried out involving 51 Hungarian gastroenterologists in May 2014. The following attributes were used to describe hypothetical choice sets: 1) type of the treatment (biosimilar/originator), 2) severity of disease, 3) availability of continuous medicine supply, 4) frequency of the efficacy check-ups. Multinomial logit model was used to differentiate between three attitude types: 1) always opting for the originator, 2) willing to consider biosimilar for biological-naïve patients only, 3) willing to consider biosimilar treatment for both types of patients. Conditional logit model was used to estimate the probabilities of choosing a given profile. RESULTS: Men, senior consultants, working in inflammatory bowel disease center and treating more patients were more likely willing to consider biosimilar for biological-naïve patients only. Treatment type (originator/biosimilar) was the most important determinant of choice for patients already treated with biologicals, and the availability of continuous medicine supply in case of biological-naïve patients. The probabilities of choosing the biosimilar with all the benefits offered over the originator under current reimbursement conditions are 89% versus 11% for new patients, and 44% versus 56% for patients already treated with biological. CONCLUSIONS: For gastroenterologist, the continuous medical supply would be one of the major benefits of biosimilars. However, benefits offered in the scenarios do not compensate for the change from the originator to the biosimilar treatment of patients already treated with biologicals.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028418
- 003
- CZ-PrNML
- 005
- 20161031122952.0
- 007
- ta
- 008
- 161005s2016 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3109/00365521.2015.1054422 $2 doi
- 024 7_
- $a 10.3109/00365521.2015.1054422 $2 doi
- 035 __
- $a (PubMed)26059967
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Baji, Petra $u a 1 Department of Health Economics, Corvinus University of Budapest , Fővám tér 8, H-1093 Budapest, Hungary, Europe. b 2 CERGE-EI Fellow, Politických vězňů 936/7 , 110 00 Praha 1-Nové Město, The Czech Republic, Europe.
- 245 10
- $a Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists / $c P. Baji, L. Gulácsi, BD. Lovász, PA. Golovics, V. Brodszky, M. Péntek, F. Rencz, PL. Lakatos,
- 520 9_
- $a OBJECTIVE: To explore preferences of gastroenterologists for biosimilar drugs in Crohn's disease. MATERIAL AND METHODS: Discrete choice experiment was carried out involving 51 Hungarian gastroenterologists in May 2014. The following attributes were used to describe hypothetical choice sets: 1) type of the treatment (biosimilar/originator), 2) severity of disease, 3) availability of continuous medicine supply, 4) frequency of the efficacy check-ups. Multinomial logit model was used to differentiate between three attitude types: 1) always opting for the originator, 2) willing to consider biosimilar for biological-naïve patients only, 3) willing to consider biosimilar treatment for both types of patients. Conditional logit model was used to estimate the probabilities of choosing a given profile. RESULTS: Men, senior consultants, working in inflammatory bowel disease center and treating more patients were more likely willing to consider biosimilar for biological-naïve patients only. Treatment type (originator/biosimilar) was the most important determinant of choice for patients already treated with biologicals, and the availability of continuous medicine supply in case of biological-naïve patients. The probabilities of choosing the biosimilar with all the benefits offered over the originator under current reimbursement conditions are 89% versus 11% for new patients, and 44% versus 56% for patients already treated with biological. CONCLUSIONS: For gastroenterologist, the continuous medical supply would be one of the major benefits of biosimilars. However, benefits offered in the scenarios do not compensate for the change from the originator to the biosimilar treatment of patients already treated with biologicals.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a monoklonální protilátky $x ekonomika $x terapeutické užití $7 D000911
- 650 _2
- $a biosimilární léčivé přípravky $x ekonomika $x terapeutické užití $7 D059451
- 650 12
- $a výběrové chování $7 D002755
- 650 _2
- $a Crohnova nemoc $x farmakoterapie $x ekonomika $7 D003424
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 12
- $a zdraví - znalosti, postoje, praxe $7 D007722
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a infliximab $x ekonomika $x terapeutické užití $7 D000069285
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a lékaři $7 D010820
- 650 _2
- $a lékařská praxe - způsoby provádění $x statistika a číselné údaje $7 D010818
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 651 _2
- $a Maďarsko $7 D006814
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Gulácsi, László $u a 1 Department of Health Economics, Corvinus University of Budapest , Fővám tér 8, H-1093 Budapest, Hungary, Europe.
- 700 1_
- $a Lovász, Barbara D $u c 3 1st Department of Medicine, Semmelweis University, Korányi Sándor utca 2a , H-1083 Budapest, Hungary, Europe.
- 700 1_
- $a Golovics, Petra A $u c 3 1st Department of Medicine, Semmelweis University, Korányi Sándor utca 2a , H-1083 Budapest, Hungary, Europe.
- 700 1_
- $a Brodszky, Valentin $u a 1 Department of Health Economics, Corvinus University of Budapest , Fővám tér 8, H-1093 Budapest, Hungary, Europe.
- 700 1_
- $a Péntek, Márta $u a 1 Department of Health Economics, Corvinus University of Budapest , Fővám tér 8, H-1093 Budapest, Hungary, Europe. d 4 Department of Rheumatology, Flór Ferenc County Hospital , Semmelweis tér 1, H-2143 Kistarcsa, Hungary, Europe.
- 700 1_
- $a Rencz, Fanni $u a 1 Department of Health Economics, Corvinus University of Budapest , Fővám tér 8, H-1093 Budapest, Hungary, Europe. e 5 Semmelweis University Doctoral School of Clinical Medicine , Üllői út 26, H-1085 Budapest, Hungary, Europe.
- 700 1_
- $a Lakatos, Péter L $u c 3 1st Department of Medicine, Semmelweis University, Korányi Sándor utca 2a , H-1083 Budapest, Hungary, Europe.
- 773 0_
- $w MED00010598 $t Scandinavian journal of gastroenterology $x 1502-7708 $g Roč. 51, č. 1 (2016), s. 22-7
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26059967 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161031122916 $b ABA008
- 999 __
- $a ok $b bmc $g 1166732 $s 953048
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 51 $c 1 $d 22-7 $e 20150610 $i 1502-7708 $m Scandinavian journal of gastroenterology $n Scand J Gastroenterol $x MED00010598
- LZP __
- $a Pubmed-20161005